Radiation oncology hypofractionation 

Preparing for changes in treatment and payment models  

Hypofractionation has demonstrated comparable outcomes to conventional regimens for prostate, bladder, breast cancers, and bone metastases. Despite strong evidence, its adoption in the U.S. lags behind other developed countries, limiting opportunities for improved patient care and operational efficiency. 

This whitepaper explores how ClinicalPath helps empower cancer centers to accelerate the adoption of hypofractionation practices, standardize care across clinical sites, and realize significant cost savings.  

Key benefits highlighted include: 

• Dramatic increases in hypofractionated whole breast irradiation adoption. 

• Doubling of single-fraction radiation use for bone metastases, enhancing patient convenience and resource utilization. 

• Workflow efficiencies that saved a large integrated cancer center over $150,000 annually.